Mingfeng Yu

Discovery of 5‐(2‐(Phenylamino)pyrimidin‐4‐yl)thiazol‐2(3<i>H</i>)‐one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation

Sarah Diab, Theodosia Teo, Malika Kumarasiri et al. · ChemMedChem · 2014 · 80 citations

Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-<i>N</i>-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation

Solomon Tadesse, Mingfeng Yu, Laychiluh Mekonnen et al. · Journal of Medicinal Chemistry · 2017 · 68 citations · Full text

Chemoprevention Strategy, Pharmacotherapy, Cell Cycle +17

Targeting CDK9 for treatment of colorectal cancer

Muhammed H. Rahaman, Frankie Lam, Long‐Jin Zhong et al. · Molecular Oncology · 2019 · 56 citations · Full text

Nontoxic Metal–Cyclam Complexes, a New Class of Compounds with Potency against Drug-Resistant <i>Mycobacterium tuberculosis</i>

Mingfeng Yu, Gayathri Nagalingam, Samantha Ellis et al. · Journal of Medicinal Chemistry · 2016 · 50 citations

Immunology, Pharmacotherapy, Chemistry +17

Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells

Theodosia Teo, Mingfeng Yu, Yuchao Yang et al. · Cancer Letters · 2014 · 43 citations

Hematological Malignancy, Pharmacologic Co-inhibition, Mixed-phenotype Acute Leukemia +4